Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: John  Mascola
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2020
Award: $4,122,850
Funding agency: National Institute of Allergy and Infectious Diseases

The Virology Core has collaborated with other intramural NIAID labs to develop a MERS-CoV Spike protein subunit vaccine. A vaccine of adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. The data indicate that induction of robust neutralizing humoral immune responses by vaccination of nave animals reduces shedding that potentially could diminish the risk of zoonotic transmission.

During the past year, we focused on isolation of monoclonal antibodies from SARS-CoV, MERS-CoV, and HKU-1 infected patients and vaccinated non-human primates. The monoclonal antibodies were analyzed for their binding and neutralization ability against different coronaviruses. This study successfully assessed some anti-coronavirus monoclonal antibodies with high potency and breath.  Those monoclonal antibodies may have potential therapeutic application in fighting infection.

Terms: <Adjuvant><Alpaca><Animals><Antibodies><Binding><Camels><Clinical Treatment Moab><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><Coronaviridae><Coronavirus><Coronavirus glycoprotein S><Coronavirus spike protein><Data><Dromedaries><Emerging Communicable Diseases><Emerging Infectious Diseases><Human><Immune response><Immunize><Immunological response><Infection><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Patients><Risk><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-Related Coronavirus><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Subunit Vaccines><Therapeutic><Transmission><Vaccinated><Vaccination><Vaccines><Viral Shedding><Virus Shedding><Zoonoses><Zoonotic><Zoonotic Infection><corona virus><coronavirus S protein><coronavirus spike glycoprotein><develop a vaccine><development of a vaccine><fighting><host response><immunoresponse><mAbs><non-human primate><nonhuman primate><pre-clinical><preclinical><severe acute respiratory syndrome-CoV><transmission process><vaccine development><vaccine formulation><virology>